Agilent Technologies (A)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-08
$129.06-1.59%
Close 2026-07-08 · 1-day change
Reading A? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track A free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-08
Reading A? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track A free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Agilent's revenue growth for fiscal year 2026 has to keep compounding to justify the price. Revenue grew 10% year over year, and the last quarter beat expectations by 5.7%. It trades at 22.6× P/E versus a peer median of 35.3×, indicating that the price reflects less growth than we forecast. A specific risk is that if Agilent reverses and cuts guidance after recently raising it, that could lead to a credibility hit, as our model puts the next-quarter miss probability at 17%. Peer multiples imply a price about 23% below where it trades.
Trailing returns as of 2026-07-08. A is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 20 analysts currently covering A (as of Jul 2026).
Based on 7 Wall Street analysts offering 12-month price targets for A in the last 4 months.
A consensus fair price across 11 valuation methods, at three horizons. Current price $129.06. As of 2026-07-09. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Advances: Revenue growth for fiscal year 2026
Earnings beat and guidance raise support revenue growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-08. EPS is implied from price ÷ P/E. Not investment advice.
Current $129.06
The last 12 months of price, then the range of analyst 12-month targets from today’s $129.06.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Revenue growth for fiscal year 2026
Upgrade indicates strong revenue growth potential.
Advances: Revenue growth for fiscal year 2026
New center and acquisition enhance growth potential in diagnostics.